Anti-D Rh0 immunoglobulin - Kamada

Drug Profile

Anti-D Rh0 immunoglobulin - Kamada

Alternative Names: Anti-D immunoglobulin - Kamada

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Kamada
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Immune thrombocytopenic purpura

Most Recent Events

  • 03 Nov 2016 KamRHO® licensed to Vitel Laboratories in Mexico before November 2016
  • 14 Jul 2016 KamRho (D) IV is still registered for Immune thrombocytopenic purpura in Argentina (Kamada Form 20-F, February 2016)
  • 25 Feb 2016 Launched for Haemolytic disease of newborn (Prevention) in Chile before February 2016 (IM) (Kamada Form 20-F, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top